Figure 2. CNS manifest synucleinopathy risk in patients with PAF.
Rates of conversion to manifest CNS synucleinopathy according to the time of onset of neurogenic orthostatic hypotension symptoms in the 74 patients from the cohort.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.